<DOC>
	<DOCNO>NCT00416663</DOCNO>
	<brief_summary>Evaluation intracoronary injection ex-vivo generate autologous Angiogenic Cells Precursors ( ACPs ) treat patient suffer severe angina responsive maximal drug treatment willing without option undergo percutaneous coronary intervention ( PCI ) coronary artery bypass graft surgery ( CABG ) . The use ACPs aim promote formation new vascularization thus viable myocardial tissue .</brief_summary>
	<brief_title>Vescell ( TM ) Treatment Patients With Severe Anginal Syndrome With Without Heart Failure</brief_title>
	<detailed_description>Ten adult patient severe angina pectoris without heart failure therapeutic alternative undergo screen treat injection Angiogenic Cell Precursors ( ACPs ) , contain VesCell ( TM ) . 250 ml blood drawn patient blood sample progenitor cell generate differentiated ACPs . The product administer obstructed coronary artery use catheter . Following injection , patient hospitalize 24-48 hour intensive care later require medical condition . Patients return follow test one , three six month follow treatment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<criteria>Patients chronic stable angina maximal medical therapy occlude coronary artery bridging collateral patent distal segment supply ischemic viable myocardial region show Sestamibi scan . On coronary angiography , occlude coronary artery bridging collateral must patent proximal segment least 30 mm least one side branch enable injection VesCellTM vessel remain occluded despite attempted angioplasty effort ( prior study angiography ) . Patients occlude target coronary artery ( without bridge collateral ) could treat PCI . Patients candidate willing undergo CABG surgery . Age 18 80 year Male nonpregnant , nonlactating female Ejection fraction &gt; 35 % Sestamibi Sestamibi scan ( myocardial perfusion ) exercise dipyridamole , demonstrate regional reversible ischemia area relate occlude coronary artery . Informed consent obtain consent form sign Patients satisfy coronary angiography Sestamibi criterion . Patient receive blood transfusion previous 4 week ( exclude potential nonautologous ACPs harvest blood ) . Inability communicate ( may interfere clinical evaluation patient ) STEMI precede 3 month PCI+stenting precede three month Significant valvular disease valve replacement After heart transplantation Cardiomyopathy Renal failure ( creatinine 10 % upper limit accord hospital normograms ) Hepatic failure Anemia ( low 11mg/dl.hemoglobin female low 12 mg/dl male ) Abnormal coagulation test normal [ platelet , PT ( INR ) , PTT ] Stroke within precede 3 year Malignancy within precede 3 year Concurrent chronic acute infectious disease Severe concurrent medical disease ( e.g. , septicemia , HIV1,2/HBV/HCV infection , insulindependent diabetes mellitus , systemic lupus erythematosus , multiple sclerosis , amyotrophic lateral sclerosis ) Chronic immunomodulating cytotoxic drug treatment Patients rectal temperature 38.40C 2 consecutive day Patient unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>Progenitor cell</keyword>
	<keyword>Angina Pectoris</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Angiogenesis</keyword>
</DOC>